Strong Revenue Growth
Total revenue in Q3 2025 was $85.8 million, representing a 17% growth year-over-year. Lymphedema revenue increased 11% to $72.4 million, and airway clearance revenue surged 71% to $13.4 million.
Gross Margin and EBITDA Increase
Gross margins increased by 80 basis points to 76%, and adjusted EBITDA rose 34% year-over-year to $14.4 million.
Guidance Raised
Full year 2025 revenue guidance is increased to $317 million to $321 million, representing growth of 8% to 10% year-over-year.
Increase in Sales Force
The total sales force expanded to 329 reps, a 25% increase in headcount, enhancing the company's ability to meet demand in strategic markets.
Innovative Product Developments
Submission of a 510(k) for next-generation AffloVest with enhancements like reduced weight and digital connectivity.
Clinical Evidence Advancements
Successful long-term data from a head and neck lymphedema RCT demonstrated the effectiveness of Flexitouch Plus, supporting future reimbursement and coverage.